The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...
Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.
A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
The symptoms of MS vary widely in location and severity among individuals. Common symptoms include fatigue, numbness, focal weakness, visual changes such as unilateral visual loss and diplopia, ...
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...
Your ability to see the world around you hinges on how well different structures in your eye perform their designated jobs. The optic nerve — actually a bundle of more than one million nerve fibers — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback